Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05555069 · ClinicalTrials.gov registry record · NA
The Impact of Menthol Flavoring on Switching in Adult Menthol Smokers
A NA study of Smoking Reduction, sponsored by Nikki Nollen, PhD, MA.
- Recruiting
- Registry status
- NA
- Development phase
- 800
- Enrollment target
- 1
- Study location
NCT05555069: Recruiting NA study of Smoking Reduction, sponsored by Nikki Nollen, PhD, MA.
NCT05555069 is a NA study of Smoking Reduction that is actively recruiting participants, run by Nikki Nollen, PhD, MA. The registered enrollment target is 800 participants, above the 208-participant average among 10 other Smoking Reduction trials with a reported enrollment target (285% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05555069, a NA study of Smoking Reduction, is actively recruiting participants, sponsored by Nikki Nollen, PhD, MA.
- RECRUITING
- Registry status
- NA
- Development phase
- 800 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will compare the efficacy of menthol-flavored versus tobacco-flavored 4th generation nicotine salt-based pod-system e-cigarettes in facilitating a switch from combustible cigarettes to e-cigarettes in adult menthol smokers.
Primary Outcome
Complete switching is defined as exclusive use of e-cigarettes, confirmed with CO\< 6ppm and predominant switching; defined as use of the e-cigarette with \>50% reduction in CPD. This will compare the effectiveness of menthol versus tobacco e-cigarettes at facilitating switching at Week 12.
Conditions Studied
Interventions
- OTHER Menthol-flavored electronic cigarette
- OTHER Tobacco-flavored electronic cigarette
Study Locations (1)
Missouri
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2022-11-08 |
| Est. Completion | 2027-03-31 |
| Phase | NA |
What NCT05555069 shows while recruiting
NCT05555069 is an interventional study that assigns participants to a tested intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, above the 208-participant average among 10 other Smoking Reduction trials with a reported enrollment target (285% higher).
The record links to 1 condition, with Smoking Reduction appearing as the primary indexed condition, and to 2 interventions - of which Menthol-flavored electronic cigarette is the first listed.
NCT05555069 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT05555069 about?
NCT05555069 is a clinical study titled "The Impact of Menthol Flavoring on Switching in Adult Menthol Smokers". This study will compare the efficacy of menthol-flavored versus tobacco-flavored 4th generation nicotine salt-based pod-system e-cigarettes in facilitating a switch from combustible cigarettes to e-cigarettes in adult menthol smokers.
What is the current status of trial NCT05555069?
This trial is currently recruiting. It is a NA study. The enrollment target is 800 participants. The study started on 2022-11-08. Estimated completion is 2027-03-31.
What conditions does trial NCT05555069 study?
This clinical trial studies the following conditions: Smoking Reduction.
What interventions are being tested in trial NCT05555069?
The interventions under investigation include: Menthol-flavored electronic cigarette (OTHER), Tobacco-flavored electronic cigarette (OTHER).
Who is sponsoring clinical trial NCT05555069?
This trial is sponsored by Nikki Nollen, PhD, MA, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05555069 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Reduction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05555069's enrollment target sits among peer trials
800 1st of 10 higher than 10 of 10 other Smoking Reduction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Reduction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia
RECRUITING · NA
-
Trauma-Informed Care for Smoking Cessation for Pregnancy
RECRUITING · NA
-
A Study Evaluating the Use of an Indoor Air Quality Monitor to Promote a Smoke-free Home
RECRUITING · NA
-
rTMS-concurrent Behavioral Priming for Reducing Smoking Cravings
RECRUITING · NA
-
Construal Level as a Novel Pathway for Affect Regulation and Cancer Control
ACTIVE NOT RECRUITING · NA
-
Tobacco Cessation in Public Housing
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI